KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Non-Current Assets (2018 - 2025)

Aurinia Pharmaceuticals' Non-Current Assets history spans 7 years, with the latest figure at $259.6 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 149.52% year-over-year to $259.6 million; the TTM value through Dec 2025 reached $541.1 million, up 21.53%, while the annual FY2025 figure was $259.6 million, 149.52% up from the prior year.
  • Non-Current Assets reached $259.6 million in Q4 2025 per AUPH's latest filing, up from $88.8 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $259.6 million in Q4 2025 to a low of $28.1 million in Q1 2023.
  • Average Non-Current Assets over 5 years is $82.8 million, with a median of $91.2 million recorded in 2025.
  • Peak YoY movement for Non-Current Assets: plummeted 34.68% in 2022, then surged 359.31% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $30.0 million in 2021, then decreased by 5.73% to $28.3 million in 2022, then soared by 335.23% to $123.3 million in 2023, then dropped by 15.59% to $104.0 million in 2024, then soared by 149.52% to $259.6 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Non-Current Assets are $259.6 million (Q4 2025), $88.8 million (Q3 2025), and $93.6 million (Q2 2025).